Abstract
The discovery that nucleic acids mediated the inhibition of gene expression in a sequence-specific manner has provided the scientific community with a potentially important tool to analyse gene function and validate drug targets. Selective inhibition of gene expression by ribozymes and small interfering RNAs (siRNAs) is being explored for potential therapeutics against viral infections, inflammatory disorders, haematological diseases and cancer. In order to be used as pharmaceutical drugs, chemical modifications are necessary to increase their stability in vivo. However, such modifications should not affect either the ribozyme cleavage activity or the incorporation of the siRNAs into the RNA interference (RNAi) targeting complex and subsequent mRNA cleavage. To attain stability, ribozymes and siRNAs must also overcome several other problems, including accessibility to target messenger RNAs (mRNAs), efficient delivery to target cells and unwanted non-specific effects.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aharinejad S, Paulus P, Sioud M, Hofmann M, Zins K, Schafer R, Stanley ER, Abraham D (2004) Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res 64:5378–5384
Arico M, Biondi A, Pui CH (1997) Juvenile myelomonocytic leukemia. Blood 90:479–488
Avgeropoulos NG, Batchelor TT (1999) New treatment strategies for malignant gliomas. Oncologist 4:209–224
Bassi GS, Mollegaard NE, Murchie AI, Lilley DM (1999) RNA folding and misfolding of the hammerhead ribozyme. Biochemistry 38:3345–3354
Beale G, Hollins AJ, Benboubetra M, Sohail M, Fox SP, Benter I, Akhtar S (2003) Gene silencing nucleic acids designed by scanning arrays: anti-EGFR activity of siRNA, ribozyme and DNA enzymes targeting a single hybridization-accessible region using the same delivery system. J Drug Target 11:449–456
Beigelman L, McSwiggen JA, Draper KG, Gonzalez C, Jensen K, Karpeisky AM, Modak AS, Matulic-Adamic J, DiRenzo AB, Haeberli P (1995) Chemical modification of hammerhead ribozymes. J Biol Chem 270:25702–25708
Bertrand E, Pictet R, Grange T (1994) Can hammerhead ribozymes be efficient tools to inactivate gene function? Nucleic Acids Res 22:293–300
Bode AM, Dong Z (2004) Targeting signal transduction pathways by chemopreventive agents. Mutat Res 555:33–51
Boyd MP, Ngok FK, Todd AV et al (2004) Critical steps in the implementation of haematopoietic progenitor-cell gene therapy using ribozyme vectors. In: Sioud M (ed) Methods in molecular biology, ribozymes and siRNA protocols, 2nd edn, vol. 252. Humana Press, New Jersey, pp 599–616
Caponigro F, French RC, Kaye SB (1997) Protein kinase C: a worthwhile target for anticancer drugs? Anticancer Drugs 8:26–33
Carr KM, Rosenblatt K, Petricoin EF, Liotta LA (2004) Genomic and proteomic approaches for studying human cancer: prospects for true patient-tailored therapy. Annu Rev Genomics Hum Genet 1:134–140
DeWever O, Mareel M (2003) Role of tissue stroma in cancer cell invasion. J Pathol 200:429–447
Dean N, McKay R, Miraglia L, Howard R, Cooper S, Giddings J, Nicklin P, Meister L, Ziel R, Geiger T, Muller M, Fabbro D (1996) Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression. Cancer Res 56:3499–3507
Dorsett Y, Tuschl T (2004) siRNAs: applications in functional genomics and potential as therapeutics. Nature 3:318–329
Eister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431:343–349
Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494–498
Fedor MJ, Uhlenbeck OC (1990) Substrate sequence effects on “hammerhead” RNA catalytic efficiency. Proc Natl Acad Sci USA 87:1668–1672
Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806–811
Flory CM, Pavco PA, Jarvis TC, Lesch ME, Wincott FE, Beigelman L, Hunt SW 3rd, Schrier DJ (1996) Nuclease-resistant ribozymes decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery to the knee joint. Proc Natl Acad Sci USA 93:745–748
Folkman J (2003) Fundamental concepts of the angiogenic process. Curr Mol Med 3:643–651
Grunweller A, Wyszko E, Bieber B, Jahnel R, Erdmann VA, Kurreck J (2003) Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2′-Omethyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res 31:3185–3193
Guschlbauer W, Jankowski K (1980) Nucleoside conformation is determined by the electronegativity of the sugar substituent. Nucleic Acids Res 8:1421–1433
Hannon GJ, Rossi JJ (2004) Unlocking the potential of the human genome with RNA interference. Nature 431:371–378
Haseloff J, Gerlach WL (1988) Simple RNA enzymes with new and highly specific endoribonuclease activity. Nature 334:585–591
Heidenreich O, Benseler F, Fahrenholz A, Eckstein F (1994) High activity and stability of hammerhead ribozymes containing 2′-modified pyrimidine nucleosides and phosphoro-thioates. J Biol Chem 269:2131–2138
Hertel KJ, Pardi A, Uhlenbeck OC et al. (1992) Numbering system for the hammerhead. Nucleic Acids Res 20:3252
Iversen PO, Emanuel PD, Sioud M(2002) Targeting Raf-1 gene expression by aDNA enzyme inhibits juvenile myelomonocytic leukemia cell growth. Blood 99:4147–4153
Kashani-Sabet M, Scanlon KJ (1995) Application of ribozymes to cancer therapy. Cancer Gene Ther 2:213–223
Kijima H, Bouffard DY, Scanlon KJ (1996) Ribozyme-mediated reversal of human pancreatic carcinoma phenotype. In: Ikehara S, Takaku F, Good RA (eds) Bone marrow transplantation-basic and clinical studies. Springer-Verlag, Tokyo, pp 153–163
Koizumi M, Ohtsuka E (1991) Effects of phosphorothioate and 2′-amino goups in hammerhead ribozymes on cleavage rates and Mg2+ binding. Biochemistry 30:5145–5150
Layzer JM, McCaffrey AP, Tanner A, Huang Z, Kay MA, Sullenger BA (2004) In vivo activity of nuclease-resistant siRNAs. RNA 10:766–771
Leirdal M, Sioud M (1999) High cleavage activity and stability of hammerhead ribozymes with a uniform 2′-amino pyrimidine modification. Biochem Biophys Res Commun 250:171–174
Leirdal M, Sioud M (2004) Gene-array analysis of glioma cells after treatment with an anti-PKCα siRNA. In: Sioud M (ed) Methods in molecular biology, ribozymes and siRNA protocols, 2nd edn, vol 252. Humana Press, Totowa, pp 493–500
Lilley DMJ (2004) Analysis of global conformational transitions in ribozymes. In Sioud M (ed) Methods in molecular biology, ribozymes and siRNA protocols. 2nd edn, vol 252. Humana Press, Totowa, pp 77–108
Logan CY, Nusse R (2004) The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20:781–810
Menger M, Tuschl T, Eckstein F, Porschke D (1996) Mg2+-dependent conformational changes in the hammerhead ribozyme. Biochemistry 35:14710–14716
Mueller MM, Fusenig NE (2004) Friends or foes-bipolar effects of the tumor stroma in cancer. Nat Rev Cancer 4:839–849
Mueller MM, Herold-Mende CC, Riede D, Lange M, Steiner HH, Fusenig NE (1999) Autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor in human gliomas with tumor progression. Am J Pathol 155:1557–1567
Murray JB, Terwey DP, Maloney L, Karpeisky A, Usman N, Beigelman L, Scott W(1998) The structural basis of hammerhead ribozyme self-cleavage. Cell 92:665–673
Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, Koyama K, Utsuno J, Baba S, Hedge P (1991) Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 253:665–669
Olsen DB, Benseler F, Aurup H, Pieken WA, Eckstein F (1991) Study of a hammerhead ribozyme containing 2′-modified adenosine residues. Biochemistry 30:9735–9741
Parekh DB, Ziegler W, Parker PJ (2000) Multiple pathways control protein kinase C phosphorylation. EMBO J 19:496–503
Parry TJ, Cushman C, Gallegos AM, Agrawal AB, Richardson M, Andrews LE, Maloney L, Mokler VR, Wincott FE, Pavco PA (1999) Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA. Nucleic Acids Res 27:2569–2577
Patzke S, Hauge H, Sioud M, Finne EF, Sivertsen EA, Delabie J, Stokke T, Aasheim HC (2004) Identification of a novel centrosome/microtubule-associated coiled-coil protein involved in cell-cycle progression and spindle organization. Oncogene 24:1159–1173
Pieken WA, Olsen DB, Benseler F, Aurup H, Eckstein F (1991) Kinetic characterization of ribonuclease-resistant 2′-modified hammerhead ribozymes. Science 253:314–317
Pritchard C, McMahon M (1997) Raf revealed in life-or-death decisions. Nat Genet 16:214–215
Pruitt K, Der CJ (2001) Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett 171:1–10
Rao JS (2003) Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 3:489–501
Raynolds A, Leake D, Boese Q et al. (2004) Rational siRNA design for RNA interference. Nat Biotechnol 22:326–330
Rebollo A, Martinez CA (1999) Ras proteins: recent advances and new functions. Blood 94:2971–2980
Scott WG, Finch JT, Klug A (1995) The crystal structure of an all-RNA hammerhead ribozyme: a proposed mechanism for RNA catalytic cleavage. Cell 81:991–1002
Sen GC (2001) Viruses and interferons. Annu Rev Microbiol 55:255–281
Sioud M(1994) Interaction between tumor necrosis factor α ribozyme and cellular proteins. J Mol Biol 242:619–629
Sioud M (1997) Effects of variations in length of hammerhead ribozyme antisense arms upon the cleavage of longer RNA substrates. Nucleic Acids Res 25:333–338
Sioud M (2004) Therapeutic siRNAs. Trends Pharmacol Sci 25:22–28
Sioud M, Jespersen L (1996) Enhancement of hammerhead ribozyme catalysis by glyceraldeyde-3-phosphate dehydrogenase. J Mol Biol 257:775–789
Sioud M, Leirdal M(1999) Substitution of the 2′-hydroxyl group at position 2.1 by an amino group interferes with Mg2+ binding and efficient cleavage by hammerhead ribozyme. Biochem Biophys Res Commun 262:461–466
Sioud M, Leirdal M (2000) Therapeutic RNA and DNA enzymes. Biochem Pharmacol 60:1023–1026
Sioud M, Sørensen DR (1998) A nuclease-resistant protein kinase Cα ribozyme blocks glioma cell growth. Nat Biotechnol 16:556–561
Sioud M, Sørensen DR (2003) Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem Biophys Res Commun 312:1220–1225
Sioud M, (2004) Therapeutic potential of siRNAs. Drugs of the future 29:1–10
Sørensen DR, Leirdal M, Sioud M (2003) Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol 327:761–766
Sözeri O, Vollmer K, Liyanage M, Frith D, Kour G, Mark GE 3rd, Stabel S (1992) Activation of the c-Raf protein kinase by protein kinase C phosphorylation. Oncogene 7:2259–2262
Ui-Tei K, Naito Y, Takahashi F, Haraguchi T, Ohki-Hamazaki H, Juni A, Ueda R, Saigo K (2004) Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res 32:936–948
Vickers TA, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF (2003) Efficient reduction of target RNAs by small interfering RNA and RNAse H-dependent antisense agents. A comparative analysis. J Biol Chem 278:7108–7118
Ways DK, Kukoly CA, deVente J, Hooker JL, Bryant WO, Posekany KJ, Fletcher DJ, Cook PP, Parker PJ (1995) MCF-7 breast cancer cells transfected with protein kinase C-α exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J Clin Invest 95:1906–1915
Werner S, Grose R (2003) Regulation of wound healing by growth factors and cytokines. Physiol Rev 83:835–870
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Sioud, M. (2006). Ribozymes and siRNAs: From Structure to Preclinical Applications. In: Erdmann, V., Barciszewski, J., Brosius, J. (eds) RNA Towards Medicine. Handbook of Experimental Pharmacology, vol 173. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-27262-3_11
Download citation
DOI: https://doi.org/10.1007/3-540-27262-3_11
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-27261-8
Online ISBN: 978-3-540-27262-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)